COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

31,221 Articles (22,733 medRxiv, 8,488 bioRxiv)

Most recent first Previous |  Page 963: Articles 9621-9630  | Next

mRNA vaccine boosting enhances antibody responses against SARS-CoV-2 Omicron variant in patients with antibody deficiency syndromes
Zimmerman, O., Altman Doss, A. M., Kaplonek, P., VanBlargan, L. A., Liang, C.-Y., Chen, R. E., Monroy, J. M., Wedner, H. J., Kulczycki, A., Mantia, T. L., O'Shaughnessy, C. C., Davis-Adams, H. G., Bertera, H. L., Adams, L. J., Raju, S., Zhao, F. R., Rigell, C. J., Biason Dy, T., Kau, A. L., Ren, Z., Turner, J., O'Halloran, J. A., Presti, R., Fremont, D. H., Kendall, P. L., Ellebedy, A. H., Alter, G., Diamond, M. S.
10.1101/2022.01.26.22269848 — Posted: 2022-01-28
Comparison of total and neutralizing SARS-CoV-2 spike antibodies against omicron and other variants in paired samples after two or three doses of mRNA vaccine
Debes, A. K., Xiao, S., Egbert, E. R., Caturegli, P., Sitaris, I., Pekosz, A., Milstone, A. M.
10.1101/2022.01.26.22269819 — Posted: 2022-01-28
Fifteen Days in December: Capture and Analysis of Omicron-Related Travel Restrictions
Schermerhorn, J., Case, A., Graeden, E., Kerr, J., Moore, M., Robinson-Marshall, S., Wallace, T., Woodrow, E., Katz, R.
10.1101/2022.01.26.22269910 — Posted: 2022-01-28
SARS-CoV-2 third vaccine immune response in MS patients treated with ocrelizumab
Brill, L., Raposo, C., Rechtman, A., Zveik, O., Levin, N., Djian, E., Wolf, D., Vaknin-Dembinsky, A.
10.1101/2022.01.26.22269876 — Posted: 2022-01-28
Mapping SARS-CoV-2 antigenic relationships and serological responses
Wilks, S. H., Muhlemann, B., Shen, X., Tureli, S., LeGresley, E. B., Netzl, A., Caniza, M. A., Chacaltana-Huarcaya, J. N., Daniell, X., Datto, M. B., Denny, T. N., Drosten, C., Fouchier, R. A. M., Garcia, P. J., Halfmann, P. J., Jassem, A., Jones, T. C., Kawaoka, Y., Krammer, F., McDanal, C., Pajon, R., Simon, V., Stockwell, M., Tang, H., van Bakel, H., Webby, R., Montefiori, D. C., Smith, D. J.
10.1101/2022.01.28.477987 — Posted: 2022-01-28
Covaxin (BBV152) Vaccine Neutralizes SARS-CoV-2 Delta and Omicron variants
Edara, V. V., Patel, M., Suthar, M. S.
10.1101/2022.01.24.22269189 — Posted: 2022-01-28 Discussion: Onsite
Is mandatory vaccination in population over 60 adequate to control the COVID-19 pandemic in E.U.?
Rachaniotis, N., Dasaklis, T., Fotopoulos, F., Chouzouris, M., Georgiadis, T., Lyberaki, A., Tinios, P.
10.1101/2022.01.25.22269867 — Posted: 2022-01-28
A longitudinal seroconversion panel shows anti-SARS-CoV-2 antibody levels up to 6.5 months after vaccination with mRNA-1273 (Moderna)
Belda, F., Mora, O., Christie, R., Crowley, M.
10.1101/2022.01.25.22269762 — Posted: 2022-01-28
SARS-CoV-2 seroprevalence in children, parents and school personnel from June 2020 to April 2021: cohort study of 55 schools in Switzerland
Ulyte, A., Haile, S. R., Blankenberger, J., Radtke, T., Puhan, M. A., Kriemler, S.
10.1101/2022.01.25.22269827 — Posted: 2022-01-28
Breadth of SARS-CoV-2 Neutralization and Protection Induced by a Nanoparticle Vaccine
Li, D., Martinez, D. R., Schäfer, A., Chen, H., Barr, M., Sutherland, L. L., Lee, E., Parks, R., Mielke, D., Edwards, W., Newman, A., Bock, K. W., Minai, M., Nagata, B. M., Gagne, M., Douek, D., DeMarco, C. T., Denny, T. N., Oguin, T. H., Rountree, W., Wang, Y., Mansouri, K., Edwards, R. J., Ferrari, G., Sempowski, G. D., Eaton, A., Tang, J., Cain, D. W., Santra, S., Pardi, N., Weissman, D., Tomai, M., Fox, C., Moore, I. N., Andersen, H., Lewis, M. G., Golding, H., Khurana, S., Seder, R., Baric, R. S., Montefiori, D. C., Saunders, K. O., Haynes, B. F.
10.1101/2022.01.26.477915 — Posted: 2022-01-28

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).